サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：網膜疾患治療の世界市場：2023-2030年
市場調査レポート
商品コード
1380424

網膜疾患治療の世界市場：2023-2030年

Global Retinal Disorder Treatment Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 198 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
網膜疾患治療の世界市場：2023-2030年
出版日: 2023年09月28日
発行: Orion Market Research
ページ情報: 英文 198 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の網膜疾患治療市場は、予測期間（2023-2030年）にCAGR 11.2％で成長すると予測されています。失明とそれに伴う罹患率との永遠の戦いにおける主な網膜疾患の治療は、過去20年間で着実に成長しています。網膜疾患に対する黄斑変性症治療の採用が増加していることは、世界の市場の成長を支える重要な要因です。それゆえ、市場プレーヤーは、市場の成長をさらに強化する黄斑変性症ベースの網膜疾患治療ソリューションの導入にも注力しています。例えば、2023年2月、補完のバイオ医薬品会社であるApellis Pharmaceuticals, Inc.は、加齢黄斑変性（AMD）に続発する地理的萎縮（GA）の治療薬として米国（FDA）からSYFOVRE（TM）（ペグセタコプラン注射剤）が承認されたと発表しました。SYFOVREは、米国で100万人以上、世界で500万人以上が罹患している失明の主な原因である地理的萎縮に対する、FDAが承認した最初で唯一の治療薬です。

国際失明予防機関（IAPB）によると、2020年には中国とインドが合わせて失明と視力障害の世界総負担の49.0%を占め、その人口は世界人口の37.0%を占める。

セグメント別の展望

黄斑変性は世界の網膜疾患治療市場で大きなシェアを占めると予測される

適応症のうち、黄斑変性サブセグメントは世界の網膜疾患治療市場でかなりのシェアを占めると予想されます。このセグメントの成長は、栄養補助食品、薬物療法、光線力学的療法（PDT）、レーザー療法など、黄斑変性症の治療が拡大していることに起因しています。米国は、患者、ヘルスケアプロバイダー、支払者、ヘルスケアシステム全体にとって重要な局面を迎えています。網膜血管障害に苦しむ患者にとって、より安価な治療選択肢ができたのです。例えば、2022年6月、バイオジェン社とサムスンバイオエピス社は、ルセンティス（R）（ラニビズマブ）のバイオシミラーであるBYOOVIZ（TM）（ラニビズマブ・ヌナ）iが米国で発売されたと発表しました。ヘルスケアプロバイダーとの連携、プロモーション活動、専門学会や患者支援団体との協力が開始され、BYOOVIZは米国内の主要な販売代理店を通じて市販されています。

地域別展望

世界の網膜疾患治療市場はさらに、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）に地域別に区分されます。なかでも北米は、高齢者人口の増加、新製品発売の増加、眼疾患に関する認知度の向上により、世界全体で大きなシェアを占めると予想されています。主な市場プレイヤーとしては、AbbVie Inc.、Genentech, Inc.、Graybug Vision, Inc.、Ocular Therapeutix、Regeneron Pharmaceuticals, Inc.などが挙げられます。

アジア太平洋地域は、世界の網膜疾患治療市場において著しいCAGRで成長すると予想されます。

すべての地域の中で、アジア太平洋地域は予測期間中にかなりのCAGRで成長すると予測されています。この地域の成長は、高いヘルスケア支出と良質な医療施設に起因しています。早期診断・早期治療に対する国民の意識の高まり、可処分所得の増加、効果的・効率的な治療法の利用可能性などが背景にあります。例えば、2021年現在、インドには7,400万人の糖尿病患者がおり、そのうち1,250万人が何らかの糖尿病性網膜症を患っています。このように、対象となる患者数が多いことが、この地域にビジネスチャンスを生み出しています。

加齢黄斑変性治療は、複数の市場プレーヤーが革新的な治療法を開発するために研究開発にますます注力していることから、有利な成長が期待されています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Allergan, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Novartis AG
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Regeneron Pharmaceuticals, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 網膜疾患治療の世界市場：適応症別
    • 糖尿病網膜症
    • 黄斑変性症
    • 網膜剥離
    • 網膜芽細胞腫
    • その他（糖尿病性眼疾患、黄斑吸引症、黄斑円孔、浮腫）
  • 網膜疾患治療の世界市場：剤形別
    • ジェル
    • アイソリューション
    • カプセル・錠剤
    • 点眼薬
    • 軟膏剤
  • 網膜疾患治療の世界市場：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン販売

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Adverum Biotechnologies
  • Aldeyra Therapeutics, Inc.
  • Alimera Sciences Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Graybug Vision, Inc.
  • Gyroscope Therapeutics Holdings PLC
  • Iveric Bio, Inc.
  • Kala Pharmaceuticals
  • Kodiak Sciences
  • Otsuka Pharmaceutical Co Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Sentis Pharma Pvt Ltd.
  • Spark Therapeutics
図表

LIST OF TABLES

  • 1. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL DIABETIC RETINOPATHY DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RETINAL MACULAR DEGENERATION DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RETINAL DETACHMENT DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL RETINAL RETINOBLASTOMA DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHERS RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 8. GLOBAL GELS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL EYE SOLUTIONS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CAPSULES & TABLETS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL EYE DROPS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL OINTMENTS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNELS, 2022-2030 ($ MILLION)
  • 14. GLOBAL RETINAL DISORDER TREATMENT IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL RETINAL DISORDER TREATMENT IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL RETINAL DISORDER TREATMENT IN ONLINE SALES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 22. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 24. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 25. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY INDICATION, 2022 VS 2030 (%)
  • 2. GLOBAL DIABETIC RETINOPATHY DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL RETINAL MACULAR DEGENERATION DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RETINAL DETACHMENT DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL RETINOBLASTOMA DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHERS RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY DOSAGE FORM, 2022 VS 2030 (%)
  • 8. GLOBAL GELS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL EYE SOLUTIONS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CAPSULES & TABLETS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL EYE DROPS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OINTMENTS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 14. GLOBAL RETINAL DISORDER TREATMENT IN HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RETINAL DISORDER TREATMENT IN RETAIL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL RETINAL DISORDER TREATMENT IN ONLINE SALES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027833

Title: Global Retinal Disorder Treatment Market Size, Share & Trends Analysis Report by Indication (Diabetic Retinopathy, Macular Degeneration, Retinal Detachment, Retinoblastoma and Other), by Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops and Ointments), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Sales),Forecast Period (2023-2030).

The global retinal disorder treatment market is anticipated to grow at a CAGR of 11.2% during the Forecast Period (2023-2030). Treating the main retinal diseases in the everlasting war against blindness and its associated morbidity has been growing steadily over the last two decades. The growing adoption of macular degeneration treatment for retinal disorder key factor supporting the growth of the market globally. Hence, the market players are also focusing on introducing macular degeneration-based retinal disorder treatment solutions that further bolster the market growth. For instance, in February 2023, Apellis Pharmaceuticals, Inc., a biopharmaceutical company in complement, announced that the US (FDA) approved SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the US and five million people globally.

According to the International Agency for the Prevention of Blindness (IAPB), in 2020, China and India together accounted for 49.0% of the global total burden of blindness and vision impairment, while their populations represent 37.0% of the global population.

Segmental Outlook

The global retinal disorder treatment market is segmented on the indication, dosage form, and distribution channel. Based on the indication, the market is sub-segmented into diabetic retinopathy, macular degeneration, retinal detachment, retinoblastoma and others (diabetic eye disease, macular pucker, macular hole, floaters). Based on the dosage form, the market is sub-segmented into gels, eye solutions, capsules & tablets, eye drops and ointments. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies and online sales. Among the dosage form, the eye solutions sub-segment is anticipated to hold a considerable share of the market owing to the rise in

The Macular Degeneration Sub-Segment is Anticipated to Hold a Considerable Share of the Global Retinal Disorder Treatment Market

Among the Indications, the macular degeneration sub-segment is expected to hold a considerable share of the global retinal disorder treatment market. The segmental growth is attributed to the growing treatments of macular degeneration including nutritional supplements, medications, photodynamic therapy (PDT) and laser therapy. US marks an important moment for patients, healthcare providers, payers, and the entire healthcare system. Patients suffering from retinal vascular disorders now have a more affordable treatment option. For instance, in June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i launched in the US. Healthcare provider engagement, promotional activity, and collaborations with professional societies and patient advocacy groups have commenced and BYOOVIZ is commercially available through major distributors across the US.

Regional Outlook

The global retinal disorder treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the growing geriatric population, the increasing launch of novel products, and enhanced awareness levels about eye conditions. The key market players include AbbVie Inc., Genentech, Inc., Graybug Vision, Inc., Ocular Therapeutix, Regeneron Pharmaceuticals, Inc. others.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Retinal Disorder Treatment Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to high healthcare expenditure and good-quality medical facilities. The increasing awareness among the population about early diagnosis & treatment, rising disposable income, and availability of effective and efficient treatment methods. For instance, as of 2021, India has 74 million diabetics, while 12.5 million of these suffer from diabetic retinopathy of some form. Thus, the presence of a high number of target patients is creating opportunities in the region.

Age-related macular degeneration treatment is expected to exhibit lucrative growth, as multiple market players are increasingly focusing on R&D to develop innovative treatments. The key market players include Kubota Pharmaceutical Holdings Co., Ltd., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Senju Pharmaceutical Co., Ltd., Sentis Pharma Pvt Ltd., Sun Pharmaceutical Industries Ltd. and others.

Market Players Outlook

The major companies serving the retinal disorder treatment market include: Allergan, Inc., Bausch Health Companies Inc., Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, AbbVie collaborated with RegenxBio to develop and market a potential one-time gene therapy, RGX-314, for treating wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global retinal disorder treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Allergan, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Regeneron Pharmaceuticals, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Retinal Disorder Treatment Market by Indication
    • 4.1.1. Diabetic Retinopathy
    • 4.1.2. Macular Degeneration
    • 4.1.3. Retinal Detachment
    • 4.1.4. Retinoblastoma
    • 4.1.5. Other (Diabetic Eye Disease, Macular Pucker, Macular Hole, Floaters)
  • 4.2. Global Retinal Disorder Treatment Market by Dosage Form
    • 4.2.1. Gels
    • 4.2.2. Eye Solutions
    • 4.2.3. Capsules & Tablets
    • 4.2.4. Eye Drops
    • 4.2.5. Ointments
  • 4.3. Global Retinal Disorder Treatment Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Online Sales

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Adverum Biotechnologies
  • 6.2. Aldeyra Therapeutics, Inc.
  • 6.3. Alimera Sciences Inc.
  • 6.4. Bausch Health Companies Inc.
  • 6.5. Biogen Inc.
  • 6.6. Clearside Biomedical, Inc.
  • 6.7. F. Hoffmann-La Roche AG
  • 6.8. Genentech, Inc.
  • 6.9. Graybug Vision, Inc.
  • 6.10. Gyroscope Therapeutics Holdings PLC
  • 6.11. Iveric Bio, Inc.
  • 6.12. Kala Pharmaceuticals
  • 6.13. Kodiak Sciences
  • 6.14. Otsuka Pharmaceutical Co Ltd.
  • 6.15. Santen Pharmaceutical Co., Ltd.
  • 6.16. Sentis Pharma Pvt Ltd.
  • 6.17. Spark Therapeutics